IMVT
Immunovant, Inc.
NASDAQ · USHealthcareBiotechnology
$39.92-0.84%
Price as of Jul 20, 2026
IMVT growth
Immunovant, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -17.5%
- EBIT
- -21.6%
- EPS
- -1.5%
- Free cash flow
- -8.1%
- Operating cash flow
- -8.4%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +10.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- -22.4%
- EBIT
- -21.6%
- Net income
- -22.2%
- EPS
- -1.5%
- Free cash flow
- -8.1%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.